NEURO61

Session information

Print

Hot Topics

[HT-15] Hot Topics 15
Toward Early Diagnosis of ALS

Wed. Sep 2, 2020 9:00 AM - 10:30 AM Room 1 (OKAYAMA CONVENTION CENTER 4F 405)

Chair：YoshikazuUgawa（Department of Human Neurophysiology, Fukushima Medical University）,HiroyukiNodera（Department of Neurology, Kanazawa Medical University, Japan）

[HT-15-1] History and Limitations of Airlie House revision of El Escorial Criteria

○Masahiro Sonoo (Department of Neurology, Teikyo University School of Medicine, Japan)

ALS has been a non-curable disease, but its disease-modifying therapy is emerging increasingly. There have been hundreds of promising therapeutic agents tested for its efficacy in animal models, but only few have been approved for humans with limited efficacy. As in Alzheimer's disease, it may not be possible to change its natural course if the regimen is started too late. To this end, the diagnosis of ALS should be made early, and more surviving motor neurons be tested for the efficacy of any agent. One of these criteria for early electrophysiological diagnosis is Awaji-criteria, and its has been shown that the diagnosis is made possible several months earlier compared with Airlie House-El Escorial criteria with similar specificity. Other disease-markers, especially for detecting upper motor neuron involvement, are now being explored. In this talk, the most updated information is reviewed on these measures for early diagnosis, which make it possible to start a potentially effective treatment for disease modification.

[HT-15-2] The revised Awaji criteria

○Hiroyuki Nodera (Department of Neurology, Kanazawa Medical University, Japan)

ALS has been a non-curable disease, but its disease-modifying therapy is emerging increasingly. There have been hundreds of promising therapeutic agents tested for its efficacy in animal models, but only few have been approved for humans with limited efficacy. As in Alzheimer's disease, it may not be possible to change its natural course if the regimen is started too late. To this end, the diagnosis of ALS should be made early, and more surviving motor neurons be tested for the efficacy of any agent. One of these criteria for early electrophysiological diagnosis is Awaji-criteria, and its has been shown that the diagnosis is made possible several months earlier compared with Airlie House-El Escorial criteria with similar specificity. Other disease-markers, especially for detecting upper motor neuron involvement, are now being explored. In this talk, the most updated information is reviewed on these measures for early diagnosis, which make it possible to start a potentially effective treatment for disease modification.

[HT-15-3] Byond Awaji Criteria

○Yoshikazu Ugawa (Department of Human Neurophysiology, Fukushima Medical University, Japan)

ALS has been a non-curable disease, but its disease-modifying therapy is emerging increasingly. There have been hundreds of promising therapeutic agents tested for its efficacy in animal models, but only few have been approved for humans with limited efficacy. As in Alzheimer's disease, it may not be possible to change its natural course if the regimen is started too late. To this end, the diagnosis of ALS should be made early, and more surviving motor neurons be tested for the efficacy of any agent. One of these criteria for early electrophysiological diagnosis is Awaji-criteria, and its has been shown that the diagnosis is made possible several months earlier compared with Airlie House-El Escorial criteria with similar specificity. Other disease-markers, especially for detecting upper motor neuron involvement, are now being explored. In this talk, the most updated information is reviewed on these measures for early diagnosis, which make it possible to start a potentially effective treatment for disease modification.

[HT-15-4] An epigenetic study of age acceleration in ALS

○Ekaterina Rogaeva1, Ming Zhang1,2, Paul M. M.. Mckeever1,3, Zhengrui Xi2, Tessa Bergsma1, Philip Mcgoldrick1,3, Julia Keith3,4, Janice Robertson1,3, Lorne Zinman3,4 (1.Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Canada, 2.Shanghai First Rehabilitation Hospital, School of Medicine and Shanghai East Hospital, School of Medicine, Tongji University, China, 3.Department of Laboratory Medicine and Pathobiology, Toronto, Canada, 4.Sunnybrook Health Sciences Centre, Toronto, Canada)

ALS has been a non-curable disease, but its disease-modifying therapy is emerging increasingly. There have been hundreds of promising therapeutic agents tested for its efficacy in animal models, but only few have been approved for humans with limited efficacy. As in Alzheimer's disease, it may not be possible to change its natural course if the regimen is started too late. To this end, the diagnosis of ALS should be made early, and more surviving motor neurons be tested for the efficacy of any agent. One of these criteria for early electrophysiological diagnosis is Awaji-criteria, and its has been shown that the diagnosis is made possible several months earlier compared with Airlie House-El Escorial criteria with similar specificity. Other disease-markers, especially for detecting upper motor neuron involvement, are now being explored. In this talk, the most updated information is reviewed on these measures for early diagnosis, which make it possible to start a potentially effective treatment for disease modification.